As a biopharmaceutical company headquartered in Allschwil/Basel, Switzerland, we have many people interested in reading more about the company in German.

Als schweizerisches Unternehmen stellen wir interessierten Personen auf dieser Seite wesentliche Informationen über unser Unternehmen in deutscher Sprache zur Verfügung.


Medieninformationen

Idorsia bietet ausgewählte Medienmitteilungen und Informationsmaterial auch in deutscher Sprache an.

Latest news

22 Apr 2021
Idorsia gibt Finanzergebnisse für das erste Quartal 2021 bekannt – markante Fortschritte bei der gesamten Pipeline – Einführungsvorbereitungen auf gutem Weg
01 Apr 2021
Idorsia veröffentlicht Ankündigung der ordentlichen Generalversammlung 2021
26 Mar 2021
The European Medicines Agency’s CHMP issues a positive opinion recommending marketing authorisation for Ponvory (ponesimod) to treat adults with relapsing forms of multiple sclerosis
19 Mar 2021
US FDA approves Ponvory (ponesimod) to treat adults with relapsing forms of multiple sclerosis
10 Mar 2021
FDA accepts the new drug application for review of Idorsia’s daridorexant for the treatment of adult patients with insomnia
03 Mar 2021
Idorsia submits European marketing authorisation application for daridorexant for the treatment of adult patients with insomnia
01 Mar 2021
Idorsia submits NDA for clazosentan to Japanese PMDA
04 Feb 2021
Idorsia gibt Finanzergebnisse für 2020 bekannt – ein erfolgreiches Jahr mit herausragenden klinischen Daten
02 Feb 2021
Idorsia reports results in relation to the Axovan arbitration – claim dismissed by Arbitral Tribunal
11 Jan 2021
Idorsia to debut at the 39th J.P. Morgan Healthcare Conference – Major catalysts expected in the near-term – Daridorexant NDA submitted to the US FDA
23 Nov 2020
Idorsia announces positive results of the two Japanese registration studies with clazosentan
27 Oct 2020
Idorsia gibt Finanzergebnisse für die ersten neun Monate 2020 bekannt
21 Oct 2020
Idorsia successfully completes capital increase with gross proceeds of CHF 535.5 million
20 Oct 2020
Idorsia announces the results of its rights offering in the context of the capital increase
08 Oct 2020
Idorsia announces capital increase to prepare for the launch of daridorexant and further fund its diversified pipeline
02 Sep 2020
Janssen announces the presentation of additional ponesimod data at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting
02 Sep 2020
Idorsia assigns and transfers agreement with ReveraGen to Santhera
31 Aug 2020
Idorsia selects Syneos Health as commercialization partner to launch daridorexant in the United States
28 Aug 2020
Daridorexant Phase 3 results in insomnia presented at SLEEP 2020
13 Aug 2020
Daridorexant Phase 3 results in insomnia to be presented at SLEEP 2020

"I enjoy working in a multicultural environment because it broadens tolerance and acceptance of different point of views. Working together with different backgrounds could assist to strike out into new directions and find innovative solutions."

Senior Research Associate, Biology